Medlab Clinical Ltd
ASX:MDC

Watchlist Manager
Medlab Clinical Ltd Logo
Medlab Clinical Ltd
ASX:MDC
Watchlist
Price: 6.6 AUD -4.21% Market Closed
Market Cap: AU$15.1m

Net Margin

-14 593.2%
Current
Declining
by 10 344.7%
vs 3-y average of -4 248.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-14 593.2%
=
Net Income
AU$-2.1m
/
Revenue
AU$14.6k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-14 593.2%
=
Net Income
AU$-2.1m
/
Revenue
AU$14.6k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Medlab Clinical Ltd
ASX:MDC
15.1m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 91% of companies in Australia
Percentile
9th
Based on 4 004 companies
9th percentile
-14 593.2%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Medlab Clinical Ltd
Glance View

Market Cap
15.1m AUD
Industry
Biotechnology

Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.

MDC Intrinsic Value
0.42 AUD
Overvaluation 94%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-14 593.2%
=
Net Income
AU$-2.1m
/
Revenue
AU$14.6k
What is Medlab Clinical Ltd's current Net Margin?

The current Net Margin for Medlab Clinical Ltd is -14 593.2%, which is below its 3-year median of -4 248.4%.

How has Net Margin changed over time?

Over the last 3 years, Medlab Clinical Ltd’s Net Margin has decreased from -895.1% to -14 593.2%. During this period, it reached a low of -14 593.2% on Jul 30, 2024 and a high of -539.7% on Jun 30, 2022.

Back to Top